Seven Grand Managers LLC Makes New Investment in Maze Therapeutics, Inc. $MAZE

Seven Grand Managers LLC purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $2,072,000. Seven Grand Managers LLC owned about 0.10% of Maze Therapeutics as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in Maze Therapeutics by 11.3% in the fourth quarter. Geode Capital Management LLC now owns 527,281 shares of the company’s stock valued at $21,850,000 after acquiring an additional 53,732 shares during the last quarter. IFP Advisors Inc bought a new position in Maze Therapeutics in the fourth quarter valued at about $146,000. PSP Research LLC bought a new position in Maze Therapeutics in the fourth quarter valued at about $525,000. ProShare Advisors LLC bought a new position in Maze Therapeutics in the fourth quarter valued at about $251,000. Finally, Falcon Wealth Planning bought a new position in Maze Therapeutics in the fourth quarter valued at about $416,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MAZE shares. Truist Financial decreased their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. JPMorgan Chase & Co. raised their price target on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. HC Wainwright raised their price target on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Trading Down 1.1%

NASDAQ MAZE opened at $26.05 on Thursday. The firm has a market cap of $1.44 billion, a P/E ratio of -10.30 and a beta of 2.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The stock’s 50-day moving average is $29.69 and its 200-day moving average is $37.61. Maze Therapeutics, Inc. has a one year low of $9.73 and a one year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Harold Bernstein sold 15,000 shares of the firm’s stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total transaction of $393,300.00. Following the sale, the chief marketing officer owned 15,000 shares of the company’s stock, valued at $393,300. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the sale, the senior vice president directly owned 12,965 shares in the company, valued at approximately $381,689.60. This represents a 16.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 119,502 shares of company stock worth $4,246,639. 5.30% of the stock is owned by company insiders.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.